SIE

209.45

+2.95%↑

AIR.FR

165.7

+2.82%↑

ENR.DE

147.6

+3.91%↑

RHM

1,475.5

-1.83%↓

HO

239.6

-0.13%↓

SIE

209.45

+2.95%↑

AIR.FR

165.7

+2.82%↑

ENR.DE

147.6

+3.91%↑

RHM

1,475.5

-1.83%↓

HO

239.6

-0.13%↓

SIE

209.45

+2.95%↑

AIR.FR

165.7

+2.82%↑

ENR.DE

147.6

+3.91%↑

RHM

1,475.5

-1.83%↓

HO

239.6

-0.13%↓

SIE

209.45

+2.95%↑

AIR.FR

165.7

+2.82%↑

ENR.DE

147.6

+3.91%↑

RHM

1,475.5

-1.83%↓

HO

239.6

-0.13%↓

SIE

209.45

+2.95%↑

AIR.FR

165.7

+2.82%↑

ENR.DE

147.6

+3.91%↑

RHM

1,475.5

-1.83%↓

HO

239.6

-0.13%↓

Search

LISI.

Uždarymo kaina

SektoriusPramonės sektorius

50.8 3.89

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

47.5

Max

51.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-14M

25M

Pardavimai

-240M

769M

P/E

Sektoriaus vid.

36.654

61.065

Dividendų pajamingumas

0.93

Pelno marža

3.22

Darbuotojai

9,537

EBITDA

-33M

106M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+25.38% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.93%

2.23%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-565M

2.3B

Ankstesnė atidarymo kaina

46.91

Ankstesnė uždarymo kaina

50.8

Naujienos nuotaikos

By Acuity

21%

79%

160 / 406 reitingas Industrials

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

LISI. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-23 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026-03-23 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026-03-23 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026-03-23 23:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-23 23:59; UTC

Rinkos pokalbiai

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026-03-23 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026-03-23 23:37; UTC

Rinkos pokalbiai

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Equities Roundup: Market Talk

2026-03-23 22:42; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026-03-23 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026-03-23 22:23; UTC

Rinkos pokalbiai

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026-03-23 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026-03-23 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026-03-23 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026-03-23 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026-03-23 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026-03-23 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026-03-23 22:08; UTC

Rinkos pokalbiai

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-23 21:42; UTC

Rinkos pokalbiai

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026-03-23 21:32; UTC

Uždarbis

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026-03-23 21:10; UTC

Svarbiausios naujienos

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026-03-23 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-23 20:50; UTC

Rinkos pokalbiai
Uždarbis
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

LISI. Prognozė

Kainos tikslas

By TipRanks

25.38% į viršų

12 mėnesių prognozė

Vidutinis 62 EUR  25.38%

Aukščiausias 62 EUR

Žemiausias 62 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines LISI. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

27.7 / 28.3Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

160 / 406 reitingas Pramonės sektorius

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę LISI.

Lisi S.A. provides assembly and component solutions for the aerospace, automotive, and medical sectors in France and internationally. It operates through three divisions: LISI Aerospace, LISI Automotive, and LISI Medical. The company offers aeronautic fastener solutions; structural components and parts for aircraft, helicopters, and airplanes; air conditioning and pressurization products, actuation and power components, helicopter rotors, landing gear structures, tanks and accumulators, and wheels and brakes; fan blades, outlet guide vanes, compressor blades, fixed vanes, variable vanes, disks, blisks, impellers, gears, inner and outer rings, and housings, as well as accessories and equipment, hot and cold section products for jet engines and turboshafts; and defense and space products. It also provides threaded fasteners, including screws, bolts, nuts, washers, special parts, etc. for industrial and automotive systems; clipped solutions, such as panel and trim fasteners, clipped nuts and screws, fasteners and connectors for cables and tubes, anti-creep rings, etc.; and braking systems, seating, occupant safety systems, fuel system components, etc. In addition, the company offers reconstruction implants and instruments, and spine and orthopedic implants; components and instruments for manual or robotic mini-invasive surgery; and components for laparoscopy, endoscopy, cardiovascular, neuro-cerebral surgery, etc. The company was formerly known as GFI Industries and changed its name to Lisi S.A. in 2002. The company was founded in 1777 and is headquartered in Belfort, France.
help-icon Live chat